文献速递胸部肿瘤

靶向赖氨酸特异性去甲基化酶1可恢复小细胞肺癌主要组织相容性复合体I类抗原呈递并克服程序性死亡配体1阻断耐药

Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
PubMed 文献 · J Thorac Oncol · 2022-06-09

小细胞肺癌(SCLC)因MHC-I表达受抑而对免疫检查点阻断(ICB)反应不佳。体外及免疫健全小鼠模型显示,抑制LSD1可恢复MHC-I表面表达、激活抗原呈递通路与干扰素信号,使SCLC细胞对MHC-I限制性T细胞杀伤敏感,并与ICB联用增强难治性SCLC模型的抗肿瘤免疫应答。

要点

  • LSD1抑制可恢复SCLC细胞MHC-I表面表达并转录激活抗原呈递通路基因。
  • LSD1抑制激活干扰素信号、诱导肿瘤内在免疫原性并增强MHC-I限制性T细胞杀伤。
  • LSD1抑制剂与ICB联用可增强难治性SCLC模型的抗肿瘤免疫应答。

核心结论

  • SCLC中MHC-I的表观遗传沉默导致其对ICB反应不佳,LSD1是MHC-I抗原呈递的调节因子,抑制LSD1可增强ICB的抗肿瘤免疫应答。

研究设计与样本

  • 体外与体内研究,评估人SCLC细胞系及免疫健全小鼠模型。

主要发现

  • 靶向抑制LSD1可恢复SCLC细胞MHC-I表面表达并转录激活抗原呈递通路基因。
  • LSD1抑制激活干扰素信号、诱导肿瘤内在免疫原性并使SCLC细胞对MHC-I限制性T细胞杀伤敏感。
  • LSD1抑制剂与ICB联用可增强难治性SCLC模型的抗肿瘤免疫应答。

临床怎么用

  • 作者认为上述数据为LSD1抑制剂与ICB联合使用以改善SCLC治疗反应提供了依据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: SCLC is a highly aggressive neuroendocrine tumor that is characterized by early acquired therapeutic resistance and modest benefit from immune checkpoint blockade (ICB). Repression of the major histocompatibility complex class I (MHC-I) represents a key mechanism driving resistance to T cell-based immunotherapies. METHODS: We evaluated the role of the lysine-specific demethylase 1 (LSD1) as a determinant of MHC-I expression, functional antigen presentation, and immune activation in SCLC in vitro and in vivo through evaluation of both human SCLC cell lines and immunocompetent mouse models. RESULTS: We found that targeted inhibition of LSD1 in SCLC restores MHC-I cell surface expression and transcriptionally activates genes encoding the antigen presentation pathway. LSD1 inhibition further activates interferon signaling, induces tumor-intrinsic immunogenicity, and sensitizes SCLC cells to MHC-I-restricted T cell cytolysis. Combination of LSD1 inhibitor with ICB augments the antitumor immune response in refractory SCLC models. Together, these data define a role for LSD1 as a potent regulator of MHC-I antigen presentation and provide rationale for combinatory use of LSD1 inhibitors with ICB to improve therapeutic response in SCLC. CONCLUSIONS: Epigenetic silencing of MHC-I in SCLC contributes to its poor response to ICB. Our study identifies a previously uncharacterized role for LSD1 as a regulator of MHC-I antigen presentation in SCLC. LSD1 inhibition enables MHC-I-restricted T cell cytolysis, induces immune activation, and augments the antitumor immune response to ICB in SCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Nguyen EM, Taniguchi H, Chan JM, et al. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. J Thorac Oncol. 2022. PMID: 35691495. doi:10.1016/j.jtho.2022.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。